Form 4: Solid Biosciences CTO Reports Equity Transactions

Solid Biosciences' Chief Technology Officer, Paul Herzich, reported the vesting and conversion of equity awards, alongside a tax-related stock sale.

Summary

• Paul Herzich, Chief Technology Officer of Solid Biosciences Inc. (SLDB), reported several equity transactions.
• On January 29, 2026, 54,925 shares of common stock were acquired through the conversion of Performance Stock Units (PSUs) after the first performance milestone was met.
• On January 31, 2026, 24,675 shares of common stock were acquired through the conversion of Restricted Stock Units (RSUs).
• On February 2, 2026, Mr. Herzich sold 26,250 shares of common stock at a weighted average price of $6.4369 per share.
• This sale was non-discretionary and executed to cover withholding taxes following the vesting of previously granted PSUs, pursuant to a pre-adopted automatic sale instruction letter.
• Mr. Herzich was granted 170,000 employee stock options on January 29, 2026, with an exercise price of $6.60, vesting over four years.
• He was also granted 85,000 Restricted Stock Units (RSUs) on January 29, 2026, vesting over four years.
• Following these transactions, Mr. Herzich beneficially owns 79,972 shares of common stock directly, 170,000 employee stock options, and 74,025 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. While there was a stock sale, it was non-discretionary and for tax purposes. The significant grants of new stock options and RSUs, along with the vesting of PSUs due to milestone achievement, indicate continued executive alignment and progress on company objectives.

Positives

• The vesting of 54,925 Performance Stock Units indicates the achievement of a business objective, as certified by the Board.
• Mr. Herzich received a new grant of 170,000 employee stock options, aligning his incentives with long-term company performance.
• Mr. Herzich received a new grant of 85,000 Restricted Stock Units, further aligning his interests with shareholder value over time.

Negatives

• A sale of 26,250 shares of common stock occurred, though it was explicitly stated to be non-discretionary and for tax withholding purposes.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on insider equity transactions and compensation events.

Industry Context

StockSavvy.ai notes that equity grants and vesting events are standard compensation practices in the biotechnology industry, particularly for key executives like a Chief Technology Officer. The structure of PSUs tied to performance milestones is a common mechanism to incentivize specific business objectives, while RSUs and stock options are typical for long-term retention and alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The grants of stock options and RSUs to the CTO align management's interests with long-term shareholder value creation. The achievement of a performance milestone for PSU vesting suggests progress on company objectives.
• Employees: The equity compensation structure reflects standard practices for executive incentives, potentially setting a precedent or benchmark for other key personnel.

Next Steps

• The newly granted employee stock options will vest over four years, with 25% vesting on the first anniversary of January 29, 2026, and 2.0833% monthly thereafter.
• The newly granted Restricted Stock Units (85,000) will vest over four years, with 25% vesting on each anniversary of January 29, 2026.
• The remaining 74,025 Restricted Stock Units (from the January 31, 2025 grant) will continue to vest annually, with 25% of the original number of shares vesting on each anniversary of the grant date until the fourth anniversary.

Key Dates

Keywords

Solid Biosciences, SLDB, Form 4, Insider Trading, Equity Compensation, Stock Options, Restricted Stock Units, Performance Stock Units, Executive Compensation, Biotechnology